What is Morgan Stanley's price target for AVIR?

Morgan Stanley's latest stated price target for Atea Pharmaceuticals Inc. (AVIR) is $6.88, from its action on Aug 13, 2024.

What is Morgan Stanley's rating on AVIR?

Morgan Stanley rates AVIR Equal-Weight, a neutral rating, as of Aug 13, 2024.

When did Morgan Stanley last change its view on AVIR?

On Aug 13, 2024, Morgan Stanley upgrades to Equal-Weight from Underweight, price target $2 to $6.88.

Analyst firms · Morgan Stanley · AVIR

Morgan Stanley AVIR price target and rating history

Atea Pharmaceuticals Inc. (AVIR) · Health Care

Morgan Stanley rates Atea Pharmaceuticals Inc. (AVIR) Equal-Weight with a $6.88 price target, as of its latest action on Aug 13, 2024. It has published 4 rating actions on AVIR since August 2021, including 1 upgrade and 2 downgrades.

Current rating: Equal-Weight
Price target: $6.88
Median target, all firms: Too few
Actions on AVIR: 4

Morgan Stanley price target on AVIR

Morgan Stanley price target on AVIR, each point a stated target, August 2021 to August 2024. Targets before January 2022 (divided by 4) are adjusted for a stock split, going by the prior target Morgan Stanley restated.

Every Morgan Stanley rating on AVIR

Aug 13, 2024
UpgradeMorgan Stanley upgrades to Equal-Weight from Underweight, price target $2 to $6.88
Jan 6, 2022
DowngradeMorgan Stanley downgrades to Underweight from Equal-Weight, price target $14 to $7
Oct 5, 2021
DowngradeMorgan Stanley downgrades to Equal-Weight from Overweight, price target $55
Aug 18, 2021
ReiterateMorgan Stanley raises its price target to $37 from $35, keeps Overweight

Questions about Morgan Stanley and AVIR

What is Morgan Stanley's price target for AVIR?: Morgan Stanley's latest stated price target for Atea Pharmaceuticals Inc. (AVIR) is $6.88, from its action on Aug 13, 2024.
What is Morgan Stanley's rating on AVIR?: Morgan Stanley rates AVIR Equal-Weight, a neutral rating, as of Aug 13, 2024.
When did Morgan Stanley last change its view on AVIR?: On Aug 13, 2024, Morgan Stanley upgrades to Equal-Weight from Underweight, price target $2 to $6.88.

More AVIR rating histories

All Morgan Stanley ratings AVIR news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.